Next Article in Journal
Connecting the Dots in the Neuroglobin-Protein Interaction Network of an Unstressed and Ferroptotic Cell Death Neuroblastoma Model
Next Article in Special Issue
Reappraisal of Human HOG and MO3.13 Cell Lines as a Model to Study Oligodendrocyte Functioning
Previous Article in Journal
The Abnormal CD4+T Lymphocyte Subset Distribution and Vbeta Repertoire in New-onset Rheumatoid Arthritis Can Be Modulated by Methotrexate Treament
Previous Article in Special Issue
GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches

Molecular Imaging of the Dopamine Transporter

Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, 56,126 Pisa, Italy
Author to whom correspondence should be addressed.
Cells 2019, 8(8), 872;
Received: 17 May 2019 / Revised: 7 August 2019 / Accepted: 9 August 2019 / Published: 10 August 2019
(This article belongs to the Special Issue The Molecular and Cellular Basis for Parkinson's Disease)
Dopamine transporter (DAT) single-photon emission tomography (SPECT) with (123)Ioflupane is a widely used diagnostic tool for patients with suspected parkinsonian syndromes, as it assists with differentiating between Parkinson’s disease (PD) or atypical parkinsonisms and conditions without a presynaptic dopaminergic deficit such as essential tremor, vascular and drug-induced parkinsonisms. Recent evidence supports its utility as in vivo proof of degenerative parkinsonisms, and DAT imaging has been proposed as a potential surrogate marker for dopaminergic nigrostriatal neurons. However, the interpretation of DAT-SPECT imaging may be challenged by several factors including the loss of DAT receptor density with age and the effect of certain drugs on dopamine uptake. Furthermore, a clear, direct relationship between nigral loss and DAT decrease has been controversial so far. Striatal DAT uptake could reflect nigral neuronal loss once the loss exceeds 50%. Indeed, reduction of DAT binding seems to be already present in the prodromal stage of PD, suggesting both an early synaptic dysfunction and the activation of compensatory changes to delay the onset of symptoms. Despite a weak correlation with PD severity and progression, quantitative measurements of DAT binding at baseline could be used to predict the emergence of late-disease motor fluctuations and dyskinesias. This review addresses the possibilities and limitations of DAT-SPECT in PD and, focusing specifically on regulatory changes of DAT in surviving DA neurons, we investigate its role in diagnosis and its prognostic value for motor complications as disease progresses. View Full-Text
Keywords: [123I]FP-CIT-SPECT; DAT; nigral cells; Parkinson’s disease; parkinsonisms [123I]FP-CIT-SPECT; DAT; nigral cells; Parkinson’s disease; parkinsonisms
Show Figures

Figure 1

MDPI and ACS Style

Palermo, G.; Ceravolo, R. Molecular Imaging of the Dopamine Transporter. Cells 2019, 8, 872.

AMA Style

Palermo G, Ceravolo R. Molecular Imaging of the Dopamine Transporter. Cells. 2019; 8(8):872.

Chicago/Turabian Style

Palermo, Giovanni, and Roberto Ceravolo. 2019. "Molecular Imaging of the Dopamine Transporter" Cells 8, no. 8: 872.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop